Long-term safety and immunologic outcomes of daily oral immunotherapy for peanut allergy

Background: Oral immunotherapy containing peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) (Palforzia [Aimmune Therapeutics, Brisbane, Calif]) for 9 to 12 months resulted in higher tolerated amounts of peanut protein in PTAH-treated individuals aged 4 to 17 years with peanut allergy than in pla...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	J. Andrew Bird, MD, Caroline Nilsson, MD, Kari Brown, MD, Trinh Pham, MS, Stephen Tilles, MD, George du Toit, MB, BCh, Amal Assa’ad, MD
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2023-08-01
Cyfres:	Journal of Allergy and Clinical Immunology: Global
Pynciau:	PTAH oral immunotherapy peanut allergy peanut (Arachis hypogaea) allergen powder pooled safety immunologic outcomes
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S2772829323000450
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!